DK1438310T3 - Beta-carbolin-derivater som PTP-inhibitorer - Google Patents

Beta-carbolin-derivater som PTP-inhibitorer

Info

Publication number: DK1438310T3
Authority: DK; Denmark
Prior art keywords: diseases; inhibitors; beta; ptpases; diabetes
Prior art date: 2001-10-19

Application number

DK02780494T

Other languages

Danish (da)

English (en)

Inventor

Robert C Andrews

Rongyuan Xie

Ravindra R Yarragunta

Tan Ren

Adnan M M Mjalli

Original Assignee

Transtech Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-19

Filing date

2002-10-18

Publication date

2007-03-26

2002-10-18 Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc

2007-03-26 Application granted granted Critical

2007-03-26 Publication of DK1438310T3 publication Critical patent/DK1438310T3/da

Links

239000003112 inhibitor Substances 0.000 title abstract 3
AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 title 1
102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 4
108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 4
201000010099 disease Diseases 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
102000018997 Growth Hormone Human genes 0.000 abstract 2
108010051696 Growth Hormone Proteins 0.000 abstract 2
230000015572 biosynthetic process Effects 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
239000000122 growth hormone Substances 0.000 abstract 2
238000003786 synthesis reaction Methods 0.000 abstract 2
208000030507 AIDS Diseases 0.000 abstract 1
208000024827 Alzheimer disease Diseases 0.000 abstract 1
208000035473 Communicable disease Diseases 0.000 abstract 1
102000004127 Cytokines Human genes 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
208000002705 Glucose Intolerance Diseases 0.000 abstract 1
206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
230000005784 autoimmunity Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Endocrinology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK02780494T 2001-10-19 2002-10-18 Beta-carbolin-derivater som PTP-inhibitorer DK1438310T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US34612501P	2001-10-19	2001-10-19
US34617601P	2001-10-19	2001-10-19
PCT/US2002/033520 WO2003033496A1 (fr)	2001-10-19	2002-10-18	Derives de beta-carboline en tant qu'inhibiteurs de ptp

Publications (1)

Publication Number	Publication Date
DK1438310T3 true DK1438310T3 (da)	2007-03-26

Family

ID=26994711

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02780494T DK1438310T3 (da)	2001-10-19	2002-10-18	Beta-carbolin-derivater som PTP-inhibitorer

Country Status (8)

Country	Link
US (2)	US6933303B2 (fr)
EP (1)	EP1438310B1 (fr)
JP (1)	JP2005508968A (fr)
AT (1)	ATE348828T1 (fr)
DE (1)	DE60216952T2 (fr)
DK (1)	DK1438310T3 (fr)
ES (1)	ES2278064T3 (fr)
WO (1)	WO2003033496A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003265398A1 (en)	2002-08-09	2004-02-25	Transtech Pharma, Inc.	Aryl and heteroaryl compounds and methods to modulate coagulation
PA8586801A1 (es)	2002-10-31	2005-02-04	Pfizer	Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
WO2004067531A1 (fr) *	2003-01-27	2004-08-12	Pfizer Inc.	Inhibiteurs de vih-integrase, compositions pharmaceutiques et methodes d'utilisation desdits inhibiteurs
WO2004071448A2 (fr) *	2003-02-12	2004-08-26	Transtech Pharma Inc.	Derives d'azole substitues comme agents therapeutiques
CA2514363A1 (fr) *	2003-02-12	2004-08-26	Transtech Pharma, Inc.	Utilisation de derives d'azoles substitues en tant qu'agents therapeutiques
US7544699B2 (en)	2003-08-08	2009-06-09	Transtech Pharma, Inc.	Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en)	2003-08-08	2007-04-24	Mjalli Adnan M M	Aryl and heteroaryl compounds, compositions, and methods of use
US7501538B2 (en)	2003-08-08	2009-03-10	Transtech Pharma, Inc.	Aryl and heteroaryl compounds, compositions and methods of use
US7141596B2 (en)	2003-10-08	2006-11-28	Incyte Corporation	Inhibitors of proteins that bind phosphorylated molecules
WO2005063748A1 (fr) *	2003-12-31	2005-07-14	Council Of Scientific And Industrial Research	Tiruchenduramine, alcaloide guanidine derivee de $g(b)-carboline
CN1910183A (zh) *	2004-01-23	2007-02-07	希龙公司	四氢咔啉化合物作为抗癌药
CA2551909C (fr) *	2004-02-12	2011-10-11	Transtech Pharma, Inc.	Derives d'azole substitues, compositions, et procedes d'utilisation
US8076353B2 (en)	2004-03-15	2011-12-13	Ptc Therapeutics, Inc.	Inhibition of VEGF translation
UA92317C2 (ru) *	2004-03-15	2010-10-25	Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК.	Производные карболина, пригодные для ингибирования развития кровеносных сосудов
US7767689B2 (en)	2004-03-15	2010-08-03	Ptc Therapeutics, Inc.	Carboline derivatives useful in the treatment of cancer
US8076352B2 (en)	2004-03-15	2011-12-13	Ptc Therapeutics, Inc.	Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7626025B2 (en)	2004-03-30	2009-12-01	Council Of Scientific And Industrial Research	Beta-carboline derived guanidine alkaloids, tiruchenduramine
CA2564356A1 (fr)	2004-04-26	2005-11-03	Pfizer Inc.	Inhibiteurs de l'enzyme integrase du vih
DE602005002746T2 (de)	2004-04-26	2008-02-07	Pfizer Inc.	Inhibitoren des hiv-integrase-enzyms
US7622581B2 (en) *	2004-05-17	2009-11-24	Tibotec Pharmaceuticals Ltd.	6,7,8,9-substituted 1-phenyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones useful as anti-infective pharmaceutical agents
KR20070034049A (ko)	2004-06-09	2007-03-27	글락소 그룹 리미티드	피롤로피리딘 유도체
NZ569329A (en)	2006-01-30	2011-09-30	Transtech Pharma Inc	Substituted imidazole derivatives and their use as PTPase inhibitors
EP2178537A4 (fr) *	2007-07-19	2011-08-17	Merck Sharp & Dohme	Dérivés de bêta-carboline en tant que composés antidiabétiques
WO2009118259A1 (fr) *	2008-03-25	2009-10-01	Merck Serono S.A.	Inhibiteurs de ptph1 pour le traitement de la maladie d'alzheimer
CN102378574B (zh)	2009-03-30	2013-11-20	转化技术制药公司	取代的偶氮蒽衍生物、药物组合物及其使用方法
WO2010138685A1 (fr)	2009-05-27	2010-12-02	Ptc Therapeutics, Inc.	Procédés pour traiter des troubles de la prostate
WO2010138652A1 (fr)	2009-05-27	2010-12-02	Ptc Therapeutics, Inc.	Méthodes de traitement du sarcome de kaposi
CA2763479A1 (fr)	2009-05-27	2010-12-02	Ptc Therapeutics, Inc.	Procedes de preparation de tetrahydro beta-carbolines substituees
MX373926B (es)	2009-05-27	2020-07-10	Ptc Therapeutics Inc	Metodos para tratar cancer y estados no neoplasicos.
WO2010147663A1 (fr) *	2009-06-16	2010-12-23	Massechusetts Institute Of Technology	Procédés et compositions d'inhibition de la prolifération de cellules aneuploïdes
US9169247B2 (en)	2009-11-20	2015-10-27	Southern Research Institute	Tetrahydro-beta-carboline derivatives, synthesis and use thereof
WO2012127885A1 (fr)	2011-03-18	2012-09-27	小野薬品工業株式会社	Dérivé de tétrahydrocarboline
CN102391323B (zh) *	2011-10-18	2013-09-25	首都医科大学	四氢-β-咔啉衍生物、其制备方法及其用途
CN103159758B (zh) *	2011-12-13	2015-08-05	首都医科大学	(1S,3S)-1-对硝基苯基-1,2,3,4-四氢-β-咔啉酰氨基酸、其合成、抗栓活性和作为抗血栓剂的应用
WO2013106460A2 (fr) *	2012-01-09	2013-07-18	University Of Washington Through Its Center For Commercialization	Compositions et procédés destinés au traitement d'astrocytomes malins
CN105153277A (zh) *	2014-06-11	2015-12-16	首都医科大学	KE修饰的β-咔啉,其制备,纳米结构,活性和应用
KR20220071293A (ko)	2016-04-01	2022-05-31	리커리엄 아이피 홀딩스, 엘엘씨	에스트로겐 수용체 조절제
US11289654B2 (en)	2016-12-22	2022-03-29	Guangzhou Chinaray Optoelectronic Materials Ltd.	Polymers containing furanyl crosslinkable groups and uses thereof
WO2018130123A1 (fr) *	2017-01-11	2018-07-19	南京圣和药业股份有限公司	Composé pentacyclique utilisé en tant que régulateur sélectif du récepteur des œstrogènes et son utilisation
EP3664803A4 (fr)	2017-08-01	2021-05-05	PTC Therapeutics, Inc.	Inhibiteur de dhodh pour utilisation dans le traitement de cancers hématologiques
KR20220044528A (ko)	2019-08-06	2022-04-08	리커리엄 아이피 홀딩스, 엘엘씨	돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제
EP4267578A4 (fr)	2020-12-23	2024-11-20	Recurium IP Holdings, LLC	Modulateurs du récepteur des éstrogènes
EP4573093A1 (fr) *	2022-08-19	2025-06-25	Olema Pharmaceuticals, Inc.	Dérivés 2,3,4,9-tétrahydro-1h-pyrido[3,4]indole utiles en tant que modulateurs des récepteurs éstrogéniques pour le traitement du cancer
CN119462646A (zh) *	2024-11-07	2025-02-18	江苏科技大学	一种取代的四氢-β-咔啉衍生物、其合成方法及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5244905A (en) *	1990-08-31	1993-09-14	Warner-Lambert Company	N-substituted cycloalkyl and polycycloalkyl polyhydro-β-carboline-phenylalanine- and phenethylamine derivatives
US5770620A (en) *	1995-06-19	1998-06-23	Ontogen Corporation	Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
US6388076B1 (en) *	1995-06-19	2002-05-14	Ontogen Corporation	Protein tyrosine phosphatase-inhibiting compounds
JP2000508302A (ja) *	1996-04-04	2000-07-04	エフ．ホフマン―ラロッシュエイジー	抗転移剤としてのテトラヒドロ―β―カルボリン誘導体の使用
CA2293400A1 (fr)	1997-06-13	1998-12-17	Gerald Mcmahon	Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine
WO1999046244A1 (fr)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulateurs de proteine tyrosine phosphatases (ptpases)

2002
- 2002-10-18 JP JP2003536235A patent/JP2005508968A/ja active Pending
- 2002-10-18 US US10/274,546 patent/US6933303B2/en not_active Expired - Fee Related
- 2002-10-18 ES ES02780494T patent/ES2278064T3/es not_active Expired - Lifetime
- 2002-10-18 WO PCT/US2002/033520 patent/WO2003033496A1/fr not_active Ceased
- 2002-10-18 EP EP02780494A patent/EP1438310B1/fr not_active Expired - Lifetime
- 2002-10-18 AT AT02780494T patent/ATE348828T1/de not_active IP Right Cessation
- 2002-10-18 DE DE60216952T patent/DE60216952T2/de not_active Expired - Fee Related
- 2002-10-18 DK DK02780494T patent/DK1438310T3/da active
2004
- 2004-12-15 US US11/012,636 patent/US20050096335A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2003033496A1 (fr)	2003-04-24
ATE348828T1 (de)	2007-01-15
US20050096335A1 (en)	2005-05-05
DE60216952D1 (de)	2007-02-01
HK1067128A1 (en)	2005-04-01
US20040014778A1 (en)	2004-01-22
DE60216952T2 (de)	2007-07-05
US6933303B2 (en)	2005-08-23
EP1438310B1 (fr)	2006-12-20
ES2278064T3 (es)	2007-08-01
EP1438310A1 (fr)	2004-07-21
JP2005508968A (ja)	2005-04-07

Publication	Publication Date	Title
DK1438310T3 (da)	2007-03-26	Beta-carbolin-derivater som PTP-inhibitorer
AU2003282234A1 (en)	2004-06-15	Benzofuran derivates, process for their preparation and intermediates thereof
EA200801372A1 (ru)	2008-08-29	Способы получения замещенных пиримидинов
MXPA06012613A (es)	2007-01-31	Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
WO2005046603A3 (fr)	2005-09-09	Composes pyridiniques
DE60219793D1 (de)	2007-06-06	Methode zur behandlung von zytokinvermittelten erkrankungen
YU37904A (sh)	2006-08-17	Benzimidazoli kao korisni inhibitori proteinske kinaze
DZ3265A1 (fr)	2000-10-19	Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2
TN2009000128A1 (en)	2010-10-18	Dihydropyridine derivatives useful as protein kinase inhibitors
YU84603A (sh)	2006-03-03	Novi inhibitori tirozin kinaze
UA83194C2 (ru)	2008-06-25	Производные пиримидина и их применение как модуляторов св2
DE60205455D1 (de)	2005-09-15	Naphthyridinderivate
DE60015508T2 (de)	2005-04-21	C-16 ungesätigte fp-selektive prostaglandin analoge
EP1441724B8 (fr)	2007-10-17	Methodes pouvant augmenter des concentrations en testosterone endogene
ATE367380T1 (de)	2007-08-15	Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
WO2024023262A3 (fr)	2024-05-02	Composés d'acide nucléique
WO2003087062A3 (fr)	2003-11-20	Composes heterocycliques, procede de preparation de ces composes et compositions pharmaceutiques les contenant, et utilisations en medecine
AU2003260436A1 (en)	2004-03-11	Pyrimidine compounds
MXPA04005809A (es)	2004-09-13	Inhibidores de proteinas quinasas.
BRPI0415355A (pt)	2006-12-12	triarilimidazóis
EA200600115A1 (ru)	2008-06-30	Производные 2-аминобензойной кислоты
DE60209886D1 (de)	2006-05-11	Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE60010934D1 (de)	2004-06-24	Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
DE50308230D1 (de)	2007-10-31	Pyrazoloisoquinolinenderivaten zur inhibierung von nfkappab-induzierende kinase
DE60326348D1 (de)	2009-04-09	Makrozyclen zur behandlung von krebserkrankungen